BRPI0519441A2 - composiÇÕes compreendendo uma epotilona, suas composiÇÕes farmacÊuticas e mÉtodos de produÇço - Google Patents

composiÇÕes compreendendo uma epotilona, suas composiÇÕes farmacÊuticas e mÉtodos de produÇço

Info

Publication number
BRPI0519441A2
BRPI0519441A2 BRPI0519441-5A BRPI0519441A BRPI0519441A2 BR PI0519441 A2 BRPI0519441 A2 BR PI0519441A2 BR PI0519441 A BRPI0519441 A BR PI0519441A BR PI0519441 A2 BRPI0519441 A2 BR PI0519441A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
epothilone
production
pharmaceutical compositions
Prior art date
Application number
BRPI0519441-5A
Other languages
English (en)
Inventor
Olaf Reer
Matthias Renz
Andreas Sachse
Claudia Sprenger
Anka Uffrecht
Jens Thomsen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0519441A2 publication Critical patent/BRPI0519441A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

COMPOSIÇÕES COMPREENDENDO UMA EPOTILONA, SUAS COMPOSIÇÕES FARMACÊUTICAS E MÉTODOS DE PRODUÇçO. A presente invenção refere-se a métodos para produção de formulações farmacêuticas de Epotilona adequadas para serem administradas parenteralmente, tal como intravenosamente.
BRPI0519441-5A 2004-12-23 2005-12-20 composiÇÕes compreendendo uma epotilona, suas composiÇÕes farmacÊuticas e mÉtodos de produÇço BRPI0519441A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04090516A EP1674098A1 (en) 2004-12-23 2004-12-23 Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
PCT/EP2005/013942 WO2006066949A1 (en) 2004-12-23 2005-12-20 Compositions comprising an epothilone and production methods

Publications (1)

Publication Number Publication Date
BRPI0519441A2 true BRPI0519441A2 (pt) 2009-01-20

Family

ID=34928859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519441-5A BRPI0519441A2 (pt) 2004-12-23 2005-12-20 composiÇÕes compreendendo uma epotilona, suas composiÇÕes farmacÊuticas e mÉtodos de produÇço

Country Status (22)

Country Link
EP (3) EP1674098A1 (pt)
JP (1) JP2008525362A (pt)
KR (1) KR20070088802A (pt)
CN (1) CN101137364B (pt)
AR (1) AR052346A1 (pt)
AU (1) AU2005318353B2 (pt)
BR (1) BRPI0519441A2 (pt)
CA (1) CA2591997A1 (pt)
CR (1) CR9211A (pt)
GT (1) GT200500386A (pt)
IL (1) IL183937A0 (pt)
MX (1) MX2007007780A (pt)
NO (1) NO20073772L (pt)
NZ (1) NZ555989A (pt)
PA (1) PA8657901A1 (pt)
PE (2) PE20100240A1 (pt)
RU (1) RU2416407C2 (pt)
SG (1) SG161207A1 (pt)
TW (1) TWI367758B (pt)
UA (1) UA88182C2 (pt)
UY (1) UY29307A1 (pt)
WO (1) WO2006066949A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DK2701720T3 (en) * 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
SMT202000058T1 (it) 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
WO2025214478A1 (zh) * 2024-04-12 2025-10-16 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19728914A1 (de) 1997-07-07 1999-01-14 Basf Ag Metallisch gefärbte Polyamide
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
TR200002299T2 (tr) * 1998-02-05 2000-11-21 Novartis Ag Epotilon kompozisyonları.
DE19820599A1 (de) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
SE517641C2 (sv) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Förfarande för att framställa ett materialskikt med barriärflikar samt ett ytskikt med sådana barriärflikar
PT1140944E (pt) 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
RU2242229C2 (ru) * 1999-01-19 2004-12-20 Новартис Аг Применение эпотилонов для лечения рака
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
MXPA01008328A (es) 1999-02-18 2002-06-04 Schering Ag Derivados de 18 -haluro epotilona, metodo para su produccion y su uso farmaceutico.
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
HUP0200583A3 (en) * 1999-03-29 2004-07-28 Bristol Myers Squibb Co A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
PE20010116A1 (es) * 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
JP2004500388A (ja) 2000-03-01 2004-01-08 スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ エポチロン、その中間体およびその類似体の合成
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2001092255A2 (en) 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2416159A1 (en) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
AU2001283275A1 (en) 2000-08-09 2002-02-18 Kosan Biosciences, Inc. Bio-intermediates for use in the chemical synthesis of polyketides
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL155306A0 (en) 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
ATE349412T1 (de) 2000-10-16 2007-01-15 R & D Biopharmaceuticals Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
EE200300323A (et) * 2001-01-25 2003-10-15 Bristol-Myers Squibb Company Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
ES2304240T3 (es) * 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
US7091193B2 (en) * 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
WO2005034964A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs

Also Published As

Publication number Publication date
AU2005318353B2 (en) 2011-09-29
RU2416407C2 (ru) 2011-04-20
WO2006066949A1 (en) 2006-06-29
UY29307A1 (es) 2006-07-31
AR052346A1 (es) 2007-03-14
HK1114015A1 (en) 2008-10-24
CN101137364A (zh) 2008-03-05
CA2591997A1 (en) 2006-06-29
EP2371365A1 (en) 2011-10-05
NO20073772L (no) 2007-09-21
PE20100240A1 (es) 2010-05-02
PA8657901A1 (es) 2007-01-17
CR9211A (es) 2007-11-23
PE20060839A1 (es) 2006-09-15
TW200635586A (en) 2006-10-16
JP2008525362A (ja) 2008-07-17
KR20070088802A (ko) 2007-08-29
TWI367758B (en) 2012-07-11
CN101137364B (zh) 2011-11-16
EP1674098A1 (en) 2006-06-28
UA88182C2 (ru) 2009-09-25
RU2007128068A (ru) 2009-01-27
IL183937A0 (en) 2007-10-31
MX2007007780A (es) 2007-08-14
NZ555989A (en) 2010-12-24
EP1827428A1 (en) 2007-09-05
AU2005318353A1 (en) 2006-06-29
GT200500386A (es) 2006-08-01
SG161207A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
BRPI0923702B8 (pt) Composições inseticidas estáveis compreendendo spinosin e uma mistura esteroisomérica de sulfoxaflor, e seu método de produção
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
MX2010009646A (es) Agentes terapeuticos antivirales.
HK1203309A1 (zh) 抗體-藥物綴合物以及相關化合物、組合物和方法
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
BR112012011328A2 (pt) inibidores de akt
NO20083726L (no) Spiroindolinon derivater
ECSP11011054A (es) Péptidos antivirales terapéuticos
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
MA32979B1 (fr) Derives aminoesterifies d'alcaloides et composition medicinale les incluant
IN2012DN03182A (pt)
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
EA201300990A1 (ru) Парентеральное введение тапентадола
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
CR9211A (es) Composiciones que comprenden una epotilona y metodos de produccion
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
ATE552832T1 (de) Antidepressivum-propharmaka
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
WO2009083664A8 (fr) Nouvelles compositions a base de taxoides
MX336359B (es) Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
BRPI0713343A2 (pt) Composições farmacêuticas contendo anticorpo monoclonal anti-idiolípico anti-ca-125 e alumínio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.